- Home
- MBWM vs CMPX Comparison
MBWM vs CMPX Comparison
Compare MBWM & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBWM | CMPX |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 863.0M | 926.7M |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MBWM | CMPX |
|---|---|---|
| Price | $49.22 | $5.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $53.63 | $14.43 |
| AVG Volume (30 Days) | 79.7K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ 10.95 | N/A |
| EPS | ★ 5.47 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.28 | N/A |
| Revenue Next Year | $4.67 | $830.89 |
| P/E Ratio | $9.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $37.76 | $1.33 |
| 52 Week High | $55.77 | $6.88 |
Technical Indicators
Market Signals| Indicator | MBWM | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 35.30 |
| Support Level | $43.14 | $4.78 |
| Resistance Level | $50.36 | $5.86 |
| Average True Range (ATR) | 1.69 | 0.31 |
| MACD | -0.53 | -0.10 |
| Stochastic Oscillator | 12.59 | 4.20 |
Price Performance
Historical ComparisonAbout MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.